Kymera Therapeutics’ (KYMR) “Outperform” Rating Reiterated at Leerink Partners

Leerink Partners reissued their outperform rating on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research report released on Friday,Benzinga reports. The firm currently has a $60.00 price target on the stock.

A number of other equities analysts have also weighed in on the stock. BMO Capital Markets assumed coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price target for the company. Guggenheim increased their target price on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Truist Financial reissued a “buy” rating and issued a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Morgan Stanley increased their price objective on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday, November 6th. Finally, UBS Group cut their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $53.88.

Kymera Therapeutics Price Performance

KYMR stock opened at $40.11 on Friday. Kymera Therapeutics has a 1 year low of $22.35 and a 1 year high of $53.27. The company has a market cap of $2.60 billion, a P/E ratio of -17.14 and a beta of 2.16. The stock’s fifty day moving average price is $45.44 and its 200-day moving average price is $43.54.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. During the same quarter in the prior year, the firm earned ($0.90) EPS. The business’s revenue for the quarter was down 20.9% compared to the same quarter last year. As a group, analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its stake in Kymera Therapeutics by 19.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company’s stock worth $4,663,000 after acquiring an additional 25,317 shares in the last quarter. Rhumbline Advisers grew its position in shares of Kymera Therapeutics by 12.4% during the 2nd quarter. Rhumbline Advisers now owns 64,535 shares of the company’s stock worth $1,926,000 after buying an additional 7,143 shares in the last quarter. Arizona State Retirement System lifted its stake in Kymera Therapeutics by 15.6% in the second quarter. Arizona State Retirement System now owns 12,830 shares of the company’s stock worth $383,000 after acquiring an additional 1,730 shares during the period. Quest Partners LLC increased its position in Kymera Therapeutics by 1,402.0% during the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock valued at $156,000 after purchasing an additional 4,865 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its position in Kymera Therapeutics by 2.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 405,870 shares of the company’s stock valued at $12,115,000 after acquiring an additional 10,731 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.